AstraZeneca buys Alexion for $39B

Pharma News: Just when Gilead Sciences’ $21 billion acquisition of Immunomedics looked to be 2020’s biggest pharma deal, AstraZeneca came up with an even larger one in acquiring Alexion Pharmaceuticals for $39 billion.

The boards of directors of both companies have unanimously approved the acquisition. Subject to receipt of regulatory clearances and approval by shareholders of both companies, the acquisition is expected to close in Q3 2021.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said “Alexion has established itself as a leader in complement biology, bringing life-changing benefits to patients with rare diseases. This acquisition allows us to enhance our presence in immunology. We look forward to welcoming our new colleagues at Alexion so that we can together build on our combined expertise in immunology and precision medicines to drive innovation that delivers life-changing medicines for more patients.”

AZ’s buying Alexion for its expertise in immune-mediated diseases. Alexion’s portfolio includes Soliris and Ultomiris and a pipeline of 11 molecules, targeting Factor D, FcRn and others.

Ludwig Hantson, Ph.D., Chief Executive Officer, Alexion, said “This transaction marks the start of an exciting new chapter for Alexion.

“We bring to AstraZeneca a strong portfolio, innovative rare disease pipeline, a talented global workforce and strong manufacturing capabilities in biologics. We remain committed to continuing to serve the patients who rely on our medicines and firmly believe the combined organisation will be well positioned to accelerate innovation and deliver enhanced value for our shareholders, patients and the rare disease communities.”

You may also like Reimagine the ‘new normal’ of HCP engagement